Sanara MedTech/$SMTI
1D1W1MYTD1Y5YMAX
Capital at risk
About Sanara MedTech
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
- Ticker
- $SMTI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 108
- Headquarters
- Fort Worth, United States
- Website
- sanaramedtech.com
Sanara MedTech Metrics
BasicAdvanced
$323M
-
-$3.69
1.16
-
Price and volume
Market cap
$323M
Beta
1.16
52-week high
$35.27
52-week low
$16.05
Average daily volume
293K
Financial strength
Current ratio
2.577
Quick ratio
2.241
Long term debt to equity
6.068
Total debt to equity
6.116
Interest coverage (TTM)
1.41%
Profitability
EBITDA (TTM)
11.889
Gross margin (TTM)
93.03%
Net profit margin (TTM)
-29.15%
Operating margin (TTM)
9.34%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
7.64%
Return on equity (TTM)
-1.32%
Valuation
Price to revenue (TTM)
2.784
Price to book
40.7
Price to tangible book (TTM)
-25
Price to free cash flow (TTM)
67.887
Free cash flow yield (TTM)
1.47%
Free cash flow per share (TTM)
0.518
Growth
Revenue change (TTM)
12.96%
Earnings per share change (TTM)
217.42%
3-year revenue growth (CAGR)
22.57%
10-year revenue growth (CAGR)
39.39%
3-year earnings per share growth (CAGR)
51.87%
10-year earnings per share growth (CAGR)
7.93%
What the Analysts think about Sanara MedTech
Analyst ratings (Buy, Hold, Sell) for Sanara MedTech stock.
Analyst projections of the future price of Sanara MedTech stock.
Bulls say / Bears say
Net revenue in Q1 2026 climbed 19% year-over-year to $27.8 million, driven by a 21% increase in soft tissue repair product sales, underscoring strong demand in its core surgical wound management segment. (Sanara IR Q1'26)
Sanara achieved GAAP net profitability in Q1 2026, reporting net income from continuing operations of $0.4 million ($0.04 per diluted share) versus a net loss of $0.6 million in Q1 2025, marking a significant earnings turnaround. (Sanara IR Q1'26)
The company reaffirmed its full-year 2026 revenue guidance of $116 million to $121 million (13%–17% growth), reflecting management’s confidence in sustaining top-line expansion. (Sanara IR Q1'26)
Bone fusion product sales declined 8% year-over-year in Q2 2026 to $2.89 million, highlighting underperformance in Sanara’s bone fusion segment. (Sanara IR Q2'26)
Operating income in Q2 2026 fell to $1.8 million from $2.5 million a year earlier, as higher SG&A and interest expenses pressured profitability despite revenue gains. (Sanara IR Q2'26)
As of June 30, 2026, Sanara held only $15.4 million in cash against $46.5 million of long-term debt, indicating high leverage and limited liquidity headroom. (Sanara IR Q2'26)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
Sanara MedTech Financial Performance
Revenues and expenses
Sanara MedTech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sanara MedTech News
AllArticlesVideos
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire2 weeks ago
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire2 months ago
Funds containing Sanara MedTech
Fund name | Fund size | $SMTI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.